Aprea Therapeutics, Inc. · NASDAQ:APRE

Aprea Therapeutics — Investor Presentation (January 2026)

23 slides from Aprea Therapeutics's investor presentation, Jan 9, 2026

1. Slide 1: Precision Oncology Through Synthetic Lethality

   1 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Precision Oncology Through Synthetic Lethality Transforming DDR Inhibition into Patient Benefit January 2026

2. Slide 2: Forward-Looking Statements

   2 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 19

3. Slide 3: Our Mission: DDR, One Critical Pathway, Multiple Targets

   3 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Our Mission DDR: One Critical Pathway - Multiple Targets DNA Damage Response (DDR) 1. Ngoi N, et al. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cancer. (2021); 7(10):930-957 Undiscl

4. Slide 4: Ushering in a New Phase of Precision Oncology - Synthetic Lethality

   4 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Ushering in a New Phase of Precision Oncology - Synthetic Lethality Synthetic Lethality • A clinically validated way to kill cancer 1 • Exploits tumor specific genetic weaknesses • Spares healthy cells • Biomarker driven identification of right p

5. Slide 5: Oncology: A Large and Growing Market Driven by Innovation

   5 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Oncology: A Large and Growing Market Driven by Innovation and Improved Therapies • Dramatic increase in life expectancy in some cancers over past 20 years • Driven by targeted therapies and smarter combinations • Shift in perception – cancer as c

6. Slide 6: Robust DDR Development Pipeline Milestones 2024-2026

   6 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust DDR Development Pipeline Milestones 2024-2026 Accomplished And Anticipated Clinical Milestones 2024 2025 2026 H1 H2 H1 H2 H1 H2 ATR ATRN-119 WEE1 APR-1051 RP2D for QD dosing ACESOT-1051: Phase 1 – Monotherapy Dose Escalation Enrolled First

7. Slide 7: Strong Drug Development and Commercial Expertise

   7 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Strong Drug Development and Commercial Expertise Experienced Team in Synthetic Lethality and Targeted Therapy Management Board of Directors Richard Peters, M.D., Ph.D. Chairman of the Board Oren Gilad, Ph.D. President and CEO Jean-Pierre Bizzari,

8. Slide 8: WEE1 Inhibitor: APR-1051

   8 © 2026 Aprea Therapeutics, Inc. All Rights Reserved 8 WEE1 Inhibitor: APR-1051 ACESOT-1051: Clinical Proof-Of-Concept

9. Slide 9: WEE1 – Clinically Validated Target: An Unmet Medical Need

   9 © 2026 Aprea Therapeutics, Inc. All Rights Reserved WEE1 – Clinically Validated Target: An Unmet Medical Need 1. AZD-1775. AstraZeneca announced in July 2022 the discontinuation of development of AZD-1775 due to its tolerability profile 2. Liu J, et al., Phase II Study of the WEE1 Inhibitor Adavos

10. Slide 10: ACESOT-1051: Phase 1 Study Design

    10 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Eligible patients ≥ 18 yo with advanced solid tumor harboring cancer-associated gene alterations CCNE1 or CCNE2 FBXW7 or PPP2R1A, KRAS-GLY12/GLY13 & TP53, and USC regardless biomarker status. HPV+ oropharyngeal squamous cell carcinoma, HPV+ cerv

11. Slide 11: ACESOT-1051: Summary of Duration of Treatment

    11 © 2025 Aprea Therapeutics, Inc. All Rights Reserved 22 42 68 104 50 57 174 25 43 47 55 55 57 48 36 50 0 30 60 90 120 150 180 210 10 mg 20 mg 30 mg 50 mg 70 mg 100 mg ACESOT-1051: Summary of Duration of Treatment (n=16) Tolcher A, et al. Early safety and efficacy of APR-1051… Mol Cancer Ther (2025

12. Slide 12: ACESOT-1051: Encouraging Single Agent Dose Response

    12 © 2026 Aprea Therapeutics, Inc. All Rights Reserved ACESOT-1051: Encouraging Single Agent Dose Response Colorectal Cancer (CRC), Head and Neck Cancer (HNSCC) Clinical Activity Observed Beginning at 70 mg Dose Dose Cohort Best Patient Tumor Response (RECIST v1.1) Indication Alteration 100 mg -15%

13. Slide 13: From Bench to Bedside #1: Preclinical Activity Observed in Early Patient Outcomes

    13 © 2026 Aprea Therapeutics, Inc. All Rights Reserved From Bench to Bedside #1: Preclinical Activity Observed in Early Patient Outcomes Pre-clinical studies with APR-1051 Data on file APR-1051 shows single agent activity in cancer cells overexpressing Cyclin E n=7 mice per group, APR-1051, 30 mg/kg

14. Slide 14: From Bench to Bedside #2: Preclinical Activity Observed in Early Patient Outcomes

    14 © 2026 Aprea Therapeutics, Inc. All Rights Reserved ays since start o enogra t or ol e 100 80 0 40 20 0 0 10 20 30 Clinical Data 70 mg Cohort HPV+ HNSCC Mouse Model From Bench to Bedside #2: Preclinical Activity Observed in Early Patient Outcomes Patient: 52-year-old Male Diagnosis: HPV+ Orophary

15. Slide 15: HPV+ Cancer – Collaboration with MD Anderson

    15 © 2026 Aprea Therapeutics, Inc. All Rights Reserved HPV+ Cancer – Collaboration with MD Anderson Ovarian Cancer* UMSCC47 tumor cells OVCAR3 tumor xenograft Tumor Volume (mm3 ) Vehicle Aprea ATRi 30 mg/kg QD Aprea WEE1i 30 mg/kg QD Combination – half dose, 15mg/kg each Days Post Treatment Tumor Vo

16. Slide 16: ATR Inhibitor: ATRN-119

    16 © 2026 Aprea Therapeutics, Inc. All Rights Reserved 16 ATR Inhibitor: ATRN-119 ABOYA-119: Clinical Proof-Of-Concept

17. Slide 17: ABOYA-119: Phase 1/2a Trial Design and Status

    17 © 2026 Aprea Therapeutics, Inc. All Rights Reserved ABOYA-119: Phase 1/2a Trial Design and Status Patient Population: Male or female subjects 12 years of age or older with solid tumors harboring any DDR mutation per NGS (or Merkel Cell Carcinoma). Potential Combinations • Radiation therapy • Anti

18. Slide 18: From Bench to Bedside: Preclinical Activity Reflected in Early Patient Outcomes

    18 © 2026 Aprea Therapeutics, Inc. All Rights Reserved From Bench to Bedside: Preclinical Activity Reflected in Early Patient Outcomes ATRN-119 shows single agent activity in cancer cells with ARID1A mutation* 200mg Cohort -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 0 20 40 60 80 100 Log10 [ATRN119] (μM) % Ac

19. Slide 19: Aprea Therapeutics

    19 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE)

20. Slide 20: Intellectual Property Portfolio, Financial Summary & Capitalization, Investment Highlights

    20 © 2026 Aprea Therapeutics, Inc. All Rights Reserved 20 Intellectual Property Portfolio Financial Summary & Capitalization Investment Highlights

21. Slide 21: Robust Global Intellectual Property Protection

    21 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust Global Intellectual Property Protection Family 1: Ataxia Telangiectasia and Rad3-Related (ATR) Protein Kinase Inhibitors • Macrocyclic inhibitors of ATR & methods of using them to treat various cancers, filed on Oct. 13th, 2015 • Patents

22. Slide 22: Financial Summary & Capitalization

    22 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Securities Common Equivalents as of November 12, 2025 Preferred Stock (as converted) 15,596 Common Stock 1 6,310,673 Warrants: Pre-Funded Tranche A Tranche B Total 507,076 1,097,394 1,097,394 2,701,864 Options 811,121 Restricted Stock Units 31,0

23. Slide 23: Investment Highlights: Financed into Q1 2027

    23 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Financed into Q1 2027 • Achieve near term inflection points and catalysts • Evaluate optimal strategic partnerships Near term catalysts • APR-1051: Q1 2026 Safety/efficacy data Q2 2026 Complete dose escalation • ATRN-119: Q4 2025 clinical update

Aprea Therapeutics — Investor Presentation (January 2026) on 6ix